Skip to content
Review

Circulating biochemical signatures of neurodegeneration in Alzheimer's disease.

2026 · International review of neurobiology · Vol 191, pp. 91-111 · 0 citations
Medicine

TL;DR

The blood-based biomarkers represent a transformative step toward early diagnosis, large-scale screening, and precision medicine in AD, with significant potential for the development of disease-modifying therapies.

View source

Similar papers

Review 2026

The clinical utility of blood-based biomarkers of Alzheimer's disease: Triumphs and pitfalls.

This chapter examines the clinical utility of key blood-based biomarkers, including phosphorylated tau, amyloid-β ratios, neurofilament light chain, and glial fibrillary acidic protein, within the context of current diagnostic frameworks.

M. M. Mir, Gulzar Muzaffar Mir, Abdul Majid et al. · 0 citations
Review 2026

Blood-based biomarkers in Alzheimer's and Parkinson's disease: From molecular pathology to therapeutic potential.

This chapter highlights a overview of blood-based biomarkers emerging in the field of AD and PD, exploring the clinical utility of core pathology markers (Aβ42/40, p-tau species, and α-synuclein), alongside other neurodegenerative markers such as neurofilament light chain and glial activation markers like GFAP.

Priya, Radhika Mittal, Jyotirmoy Banerjee et al. · 0 citations
Review Open access Sep 2026

Alzheimer’s Disease in the Era of Geroscience: Mechanisms, Biomarkers, and Therapeutic Prospects

This narrative review examines AD mechanisms, biomarkers, and therapeutic prospects from a geroscience perspective and applies the eight hallmarks of neurodegenerative diseases as an analytical framework to establish which preventive strategies and biomarker-guided, stage-matched combination therapies improve clinicall...

P. Chmielewski · 0 citations
Review 2026

The emerging landscape of circulatory biomarkers in Alzheimer's disease.

This chapter explores the pathophysiology of Alzheimer's Disease to identify peripheral molecular markers associated with these early events and facilitate the development of combinatorial therapies.

Sakshi Kumari, Amaan Rais, Mohd Suhail Ashar et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.